Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD footcare case

This article was originally published in The Tan Sheet

Executive Summary

Profoot Footcare Products' labeling claim that Triad Insoles "relieves knee, leg and back pain" should be discontinued due to lack of supporting scientific evidence, National Advertising Division says in recent NAD Case Reports. Dr. Scholl's marketer Schering-Plough challenged the claim, asserting it is "unqualified and overly broad as it does not distinguish" between different types of pain. Although Profoot explained the Triad design "incorporates a cupped heel for foot stability and an anatomically conforming supportive arch" to alleviate joint pressure, NAD agrees with Schering based on lack of clinical data. Profoot, while disagreeing, said it would amend the claim in future packaging...

You may also be interested in...

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

New Real-World Data Show Benefits Of Abbott's FreeStyle Libre Technology

New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts